| |
Gilead's New HCV Study - 4 Drug Regimen - GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection - 3 new oral HCV drugs from Gilead: NS5A, protease + NNRTI + ribavirin
|
| |
| |
This study is currently recruiting participants.
Verified on May 2011 by Gilead Sciences
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.
http://clinicaltrials.gov/ct2/show/NCT01353248
Here is data reported on the 3 Gilead new oral HCV drugs:
Three-Day, Dose-Ranging Study of the HCV NS5A Inhibitor GS-5885 - (04/06/11)
Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451 - (04/06/11)
Antiviral, pharmacokinetic and safety data for GS-9190, a non nuke... - [ Diese Seite ubersetzen ] Bavisotto L, Wang C, Jacobson I, Marcellin P, Zeuzem S, Lawitz S, Lunde NM, Sereni P, O'Brien C, Oldach D, Rhodes G and the GS-9190 Study Team ... www.natap.org/2007/AASLD/AASLD_39.htm
|
|
| |
| |
|
|
|
